Reles, Angela : MOLECULAR GENETIC ALTERATIONS IN OVARIAN CANCER The Role of the p53 Tumor Suppressor Gene and the mdm2 Oncogene



Agorastos, T., Lambropoulos, A.F., Constantinidis, T.C., Kotis, A., and Bontis, J.N. "P53 codon 72 polymorphism and risk of intra-epithelial and invasive cervical neoplasia in Greek women." Eur. J. Cancer Prev. 9: 113-118 , 2000

Ahuja, H.G., Testa, M.P., and Cline, M.J. "Variation in the protein coding region of the human p53 gene" . Oncogene 5: 1409-1410 , 1990

Angelopoulou, K., Levesque, M.A., Katsaros, D., Shipman, R., and Diamandis, E.P . "Exon 5 of the p53 gene is a target for deletions in ovarian cancer" . Clin. Chem . 44 : 72-77 , 1998

Aunoble, B., Sanches, R., Didier, E., and Bignon, Y.-J ". Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (Review)." Int. J. Oncol . 16: 567-576 , 2000

Anttila, M.A., Ji, H., Juhola, M.T., Saarikoski, S.V., and Syrjänen, K.J. "The prognostic significance of p53 expression quantitated by computerized image analysis in epithelial ovarian cancer." Int. J. Gynecol. Pathol . 18 : 42-51 , 1999

Argentini, M., Barboule, N., and Wasylyk, B . "The contribution of the RING finger domain of MDM2 to cell cycle progression" . Oncogene 19: 3849-3857, 2000

Arrowsmith, C., and Morin, P ". New insights into p53 function from structural studies." Oncogene 12: 1379-1385 , 1996

Averette, H.E., Janicek, M.F., and Menck, H.R . "The national cancer data base report of ovarian cancer" . Cancer 76 : 1096-1103 , 1995

Avigad, S., Barel, D., Blau, O., Malka, A., Zoldan, M., Mor, C., Fogel, M., Cohen, I.J., Stark, B., Goshen, Y., Stein, J., and Zaizov, R. A "novel germ line p53 mutation in intron 6 in diverse childhood malignancies" . Oncogene 14: 1541-1545 , 1997

Bakalkin, G., Yakovleva, T., Selivanova, G., Magnusson, K.P., Szekely, L., Kiseleva, E., Klein, G., Terenius, L., and Wiman, K.G . "p53 binds single-stranded DNA ends and catalyzes DNA renaturation and strand transfer." Proc. Natl. Acad. Sci . USA 91 : 413-417 , 1994

Baylin, S.B. "Tying it all together: epigenetics, genetics, cell cycle, and cancer. Science" 277 : 1948-1949 , 1997

Beenken, S.W., Karsenty, G., Raycroft, L., and Lozano, G. "An intron binding protein is required for transformation ability of p53" . Nucleic Acids Res. 19: 4747-4752, 1991

Berchuck, A., Schildkraut, J.M., Marks, J.R., and Futreal, P.A ". Managing hereditary ovarian cancer risk." Cancer 86 : 2517-24 , 1999

Bergh, J., Norberg, T., Sjogren, S., Lindgren, A., and Holmberg, L ". Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy" . Nature Med . 1 : 1029-1034 , 1995


Beroud, C., Verdier, F., and Soussi, T. "p53 gene mutation: software and database. " Nucl. Acids Res . 24: 147-150 , 1996

Blandino, G., Levine, A.J., and Oren, M . "Mutant gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy." Oncogene 18: 477-485 , 1999

ten Bokkel Huinink, W., Gore, M., Carmichael, J., Gordon, A., Malfetano, J., Hudson, I., Broom, C., Scarabelli, C., Davidson, N., Spanczynski, M., Bolis, G., Malmström, H., Coleman, R., Fields, S.C., and Heron, J.-F . "Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer" . J. Clin. Oncol . 15 : 2183-2193, 1997

Bosari, S., Viale, G., Radaelli, U., Bossi, P., Bonoldi, E., and Coggi, G. "p53 accumulation in ovarian carcinomas and its prognostic implications" . Human Pathol . 24: 1175-1179, 1993

Brown, C.R., Doxsey, S.J., White, E., and Welch, W.J. "Both viral (adenovirus E1B) and cellular (hsp 70, p53) components interact with centrosomes" . J. Cell. Physiol . 160: 47-60 , 1994

Buckbinder, L.R., Talbott, S., Velasco-Miguel, I., Takenaka, B., Faha, B., Seizinger, B.R., and Kley, N. "Induction of the growth inhibitor IGF-binding protein 3 by p53." Nature 377: 646-649, 1995

Buller, R.E., Sood, A., Fullenkamp, C., Sorosky, J., Powills, K., and Anderson, B. "The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis." Cancer Gene Therapy 4: 239-245 , 1997

Burghardt, E., Girardi, F., Lahousen, M., Tamussino, K., and Stettner, H ". Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer." Gynecol. Oncol. 40 : 103-106, 1991

Buttitta, F., Marchetti, A., Gadducci, A., Pellegrini, S., Morganti, M., Carnicelli, V., Cosio, S., Gagetti, O., Genazzani, A.R., and Bevilacqua, G ". p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study." Br. J. Cancer 75 : 230-235 , 1997

Cahilly-Snyder, L., Yang-Feng, T., Francke, U., and George, D . "Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line." Somat. Cell. Mol. Genet . 13: 235-244 , 1987

Canman, C.E., Lim, D.-S., Cimprich, K.A., Taya, Y., Tamai, K., Sakaguchi, K., Appella, E., Kastan, M.B., and Siliciano, J.D . "Activation of the ATM kinaseby ionizing radiation and phosphorylation of p53" . Science 281 : 1677-1679 , 1998

Carbone, D., Chiba, I., and Mitsudomi, T ". Polymorphism at codon 213 within the p53 gene, " Oncogene 6: 691-692 , 1991

Casey, G., Lopez, M., Ramos, J., Plummer, S., Arboleda, M., Shaughnessy, M., Karlan, B., and Slamon, D. "DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies" . Oncogene 13: 1971-1981, 1996


Chen, C.-Y., Oliner, J.D., Zhan, Q., Fornace, A.J.Jr., Vogelstein, B., and Kastan, M.B. "Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway." Proc. Natl. Acad. Sci . 91: 2684-2688 , 1994

Chen, J., Marechal, V., and Levine, A. "Mapping of the p53 and mdm-2 interaction domains" . Mol. Cell. Biol . 13: 4107-4114, 1993

Chen, J., Lin, J., and Levine, A.J . "Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene." Mol. Med . 1 : 142-152 , 1995

Chen, J., Wu, X., Lin, J., and Levine, A. "Mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein." Mol. Cell. Biol . 16 : 2445-2452 , 1996

Chen, L., Agrawal, S., Zhou, W., Zhang, R., and Chen, J. "Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage" . Proc. Natl. Acad. Sci . USA 95: 195-200 , 1998

Chen, X., Ko, L.J., Jayaraman, L., and Prives, C. "p53 levels, functional domains, and DNA.damage determine the extent of the apoptotic response of tumor cells. " Genes Dev. 10 : 2438-2451 , 1996

Cho, Y., Gorina, S., and Pavletich, N. "Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations" . Science 265 : 346-355 , 1994

Chuaqui, R.F., Zhuang, Z., and Merino, M.J . "Molecular genetic events in the developement and progression of ovarian cancer in humans." Mol. Med. Today 3: 207-13 , 1997

Clement, P.B ". Histology of the ovary. " Am. J. Surg. Pathol. 11: 277 , 1987

Cobleigh, M.A., Vogel, C.L., Tripathy, D., Robert, N.J., Scholl, S., Fehrenbacher, L., Wolter, J.M., Paton, V., Shak, S., Lieberman, G., and Slamon, D.J. "Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. " J. Clin. Oncol. 17 : 2639-2648 , 1999

Conklin, D.S., Galaktionov, K., and Beach, D . "14-3-3 proteins associate with cdc25 phosphatases" . Proc. Natl. Acad. Sci . USA 29 : 7892-7896 , 1995

Cordon-Cardo, C., Latres, E., Drobnjak, M., Oliva, M., Pollack, D., Woodruff, J., Marechal, V., Chen, J., Brennan, M., and Levine, A. "Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas." Cancer Res. 54 : 794-799 , 1994

Counts, J.L., and Goodman, J.I ". Alterations in DNA methylation may play a variety of roles in carcinogenesis" . Cell 83: 13-15 , 1995

Cox, D.R. "Regression models and life-tables" , J. R. Stat. Soc. [B] 34 : 187-220 , 1972

Cross, S.M., Sanchez, C.A., Morgan, C.A., Schimke, M.K., Ramel, S., Idzerda, R.L., Raskind, W.H., and Reid, B.J ". A p53 dependent mouse spindle checkpoint" . Science 267: 1353-1356 , 1995


Dang, C.V ". c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol." Cell. Biol . 19 : 1-11, 1999

DiCioccio, R.A., Werness, B.A., Allen, H.J., and Piver, M.S . "Correlation of TP53 mutations and p53 expression in ovarian tumors." Cancer Genet. Cytogenet. 105 : 93-102, 1998

DiCioccio, R.A., and Piver, M.S. "A polymorphism in intron 2 of the TP53 gene." Clinical Genetics 50: 108-109 , 1996

Dong, Y., Walsh, M.D., McGuckin, M.A., Cummings, M.C., Gabrielli, B.G., Wright, G.R., Hurst, T., Khoo, S.K., and Parsons, P.G ". Reduced expression of Retinoblastoma Gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer" . Int. J. Cancer 74: 407-415 , 1997

Druck, T., Hadaczek, P., Fu, T.-B., Ohta, M., Siprashvilli, Z., Baffa, R., Negrini, M., Kastury, K., Veronese, M.L., Rosen, D., Rothstein, J., McCue, P., Cotticelli, M.G., Inoue, H., Croce, C.M., and Huebner, K . "Structure and expression of the human FHIT gene in normal and tumor cells." Cancer Res . 57 : 504-512, 1997

Easton, D.F., Ford, D., and Bishop, D.T. "Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium." Am. J. Hum. Genet . 56 : 265-271, 1995

Eccles, D., Breet, L., Lessells, A., Gruber, L., Lane, D., Steel, C., and Leonard, R. "Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma" . Br. J. Cancer 65 : 40-44, 1992

Eisenkop, S.M., Friedman, R.L., and Wang, H.J. "Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study" . Gynecol. Oncol . 69: 103-108,.1998

El-Deiry, W.S., Kern, S.E., Pietenpol, J.A., Kinzler, K.W., and Vogelstein, B. "Definition of a consensus binding site for p53" . Nature Genet . 1 : 45-49 , 1992

El-Deiry, W.S., Tokino, T., Velculescu, V.E., Levy, D.B., Parsons, R., Trent, J.M., Lin, D., Mercer, W.E., Kinzler, K.W., and Vogelstein, B . "WAF1, a potential mediator of p53 tumor suppression" . Cell 75 : 817-825 , 1993

El-Deiry, W.S . "Regulation of p53 downstream genes" . Sem. Cancer Biol . 8: 345-357 , 1998

Elenbaas, B., Dobbelstein, M., Roth, J., Shenk, T., and Levine, A.J. "The MDM2 oncoprotein binds specifically to RNA through its RING finger domain" . Mol. Med. 2: 439-451 , 1996

Eltabakkah, G.H., Belinson, J.L., Kennedy, A.W., Biscotti, C.V., Casey, G., Tubbs, R.R., and Blumenson, L.E ". p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer" . Cancer 80 : 892-898 , 1997

Fakharzadeh, S.S., Trusko, S.P., and George, D.L . "Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line" . EMBO J. 10 : 1565-1569, 1991


Fathalla, M.F ". Incessant ovulation - a factor in ovarian neoplasia?" Lancet 2 : 163 , 1971

Felix, C., Brown, D., Mitsudomi, T., Ikagaki, N., Wong, A., Wasserman, R., Womer, R., and Biegel, J ". Polymorphism at codon 36 of the p53 gene" . Oncogene 9: 327-328, 1994

Ferrandina, G., Fagotti, A., Salerno, M.G., Natali, P.G., Mottolese, M., Maneschi, F., De Pasqua, A., Benedetti-Panici, P., Mancuso, S., and Scambia, G. "p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer." Br. J. Cancer 81 : 733-740 , 1999

Fong, K., Biesterveld, E., Vermani, A., Wistuba, I., Sekido, Y., Bader, S., Ahmadian, M., Ong, S., Rassool, F., Zimmerman, P., Giaccone, G., Gazdar, A., and Minna, J. "FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are asociated with cancer related FHIT cDNA splicing abberations. " Cancer Res . 57 : 2256-2267 , 1997

Ford, D., Easton, D.F ". The genetics of breast and ovarian cancer." Br. J. Cancer 72 : 805-812, 1995

Ford, D., Easton, D.F., Stratton, M., Narod, S., Goldgar, D., Devilee, P., Bishop, D.T., Weber, B., Lenoir, G., Chang-Claude, J., Sobol, H., Teare, M.D., Struewing, J., Arason, A., Scherneck, S., Peto, J., Rebbeck, T.R., Tonin, P., Neuhausen, S., Barkardottir, R., Eyfjord, J., Lynch, H., Pander, B.A., Gayther, S.A., and Zelada-Hedman, M . "Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families" . The Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 62: 676-689 , 1998

Foster, B.A., Coffey, H.A., Morin, M.J., Rastinejad, F . "Pharmacological rescues of mutant p53 conformation and function" . Science 286 : 2507-2510 , 1999

Foulkes, W., Stamp, G., Afzal, S., Lalani, N., McFarlane, C., Trowsdale, J., and Campbell, I. "MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status." Br. J. Cancer 72: 883-888 , 1995

Freedman, D.A., Epstein, C.B., Roth, J.C., and Levine, A.J. "A genetic approach to mapping the p53 binding site in the mdm2 protein." Mol. Med . 3 : 248-259 , 1997

Freedman, D.A., Wu, L., and Levine, A.J ". Functions of the MDM2 oncoprotein." Cell. Mol. Life Sci. 55: 96-107 , 1999

Fujita, M., Enomoto, T., Inoue, M., Tanizawa, O., Ozaki, M., Rice, J., and Nomura, T. "Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinoma than in other common epithelial tumors of the human ovary" . Jpn. J. Cancer Res. 85: 1247-1256, 1994

Fukasawa, K., Choi, T., Kuriyama, R., Rulong, S., and Vande Woude, G.F . "Abnormal centrosome amplification in the absence of p53" . Science 271: 1744-1747 , 1996

Gallagher, W.M., Cairney, M., Schott, B., Roninson, I.B., and Brown, R ". Identification of p53 genetic suppressor elements which confer resistance to cisplatin." Oncogene 14: 185-193, 1997


Gayther, S.A., Barski, P., Batley, S.J., Li, L., de Foy, K.A.F., Cohen, S.N., Ponder, B.A.J., and Caldas, C ". Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumours." Oncogene 15 : 2119-2126, 1997

Ge, H., Wong, M.P., Lam, W.K., Lee, J., Fu, K.H., Yew, W.W., and Lung, M.L . "p53 intron 2 genotypes detected in normal specimens and lung carcinomas in Hong Kong." Oncol. Rep . 5 : 1265-1267, 1998

Geisler, J.P., Geisler, H.E., Wiemann, M.C., Givens, S.S., Zhou, Z., and Miller, G.A. "Quantification of p53 in epithelial ovarian cancer" . Gynecol. Oncol . 66: 435-438, 1997

Geisler, J.P., Geisler, H.E., Miller, G.A., Wiemann, M.C., Zhou, Z., and Crabtree, W ". p53 and bcl-2 in epithelial ovarian carcinoma: their value as prognostic indicators at a median follow-up of 60 months. " Gynecol. Oncol . 77: 278-282 , 2000

Gershenson, D.M., Deavers, M., Diaz, S., Tortolero-Luna, G., Miller, B.E., Bast, R.C., Mills, G.B., and Silva, E.G ". Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors" . Clin. Cancer Res . 5: 4053-4058, 1999

Goff, B.A., Ries, J.A., Els, L.P., Coltrera, M.D., and Gown, A.M. "Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure" . Gynecol. Oncol . 70: 378-385 , 1998

Goh, H., Yao, J., and Smith, D. "p53 point mutation and survival in colorectal cancer patients" . Cancer Res . 55: 5217-5221 , 1995

Gottlieb, E., and Oren, M. "p53 facilitates pRb cleavage in IL-3-deprived cells: novel pro-apoptotic activity of p53" . EMBO J . 17: 3587-3596 , 1998

Gottlieb, E. and Oren, M. "p53 and apoptosis" . Sem. Cancer Biol . 8: 359-368 , 1998

Graeber, A., Osmanian, C., Jacks, T., Housman, D., Koch, C., Lowe, S., and Graccia, A. "Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors" . Nature 379 , 88-91, 1996

Greenblatt, M., and Harris, C ". Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis" . Cancer Res . 54 : 4855-4878 , 1994

Gu, J., Chen, D., Rosenblum, J., Rubin, R.M., and Yuan, Z.-M. "Identification of a sequence element from p53 that signals for Mdm2 targeted degradation" . Mol. Cell. Biol. 20: 1243-1253, 2000

Gudas, J.M., Nguyen, H., Klein, R.C., Katayose, D., Seth, P., and Cowan, K.H. "Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells." Clin. Cancer "Res." 1 : 71-80 , 1995

Güssow, D., Rein, R., Ginjaar, I., Hochstenbach, F., Seemann, G., Kottman, A., and Ploegh, H.L. "The human beta2-Microglobulin gene. Primary structure and definition of the transcriptional unit. " J. Immunol. 139 : 3132-3138 , 1987


Guidos, C.J., Williams, C.J., Grandal, I., Knowles, G., Huang, M.T.F., and Danska, J.S. "V(D)J recombination activates a p53-dependent DNA damage checkpoint in scid lymphocyte precursors" . Genes Dev . 10: 2038-2054, 1996

Gurnani, M., Lipari, P., Dell, J., Shi, B., and Nielsen, L.L . "Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, breast and prostate cancer." Cancer Chemother. Pharmacol. 44 :143-151 , 1999

Hall, J., Lee, M., Newman, B., Morrow, J., Huey, B., and King, M.C. "Linkage of early onset familial breast cancer to chromosome 17q21" . Science 250 : 1684-1689 , 1990

Halpern, J. "Maximally selected chi square statistics for small samples." Biometrics 38 : 1017-1023 , 1982

Hagopian, G.S., Mills, G.B., Khokhar, A.R., Bast, R.C., and Siddik, Z.H. "Expression of p53 in Cisplatin-resistant ovarian cancer cell lines: Modulation with the novel platinum analogue (1R,2R-Diaminocyclohexane)(trans-diacetato)(dichloro)-platinum (IV)." Clin. Cancer Res . 5: 655-663 , 1999

Harlow, E., Williamson, N.M., Ralston, R., Helfman, D.M., and Adams, T.E. "Molecular cloning and in vitro expression of a cDNA clone for human cellular antigen p53." Mol. Cell. Biol . 5 : 1601-1610 , 1985

Harris, N., Brill, E., Shohat, O., Prokocimer, M., Wolf, D., Arai, N., and Rotter, V. "Molecular Basis for heterogenecity of the human p53 protein. " Mol. Cell. Biol . 6: 4650-4656, 1986

Hartmann, L., Podratz, K., Keeney, G., Kamel, N., Edmonson, J., Grill, J., Su, J., Katzmann, J., and Roche, P ". Prognostic significance of p53 immunostaining in epithelial ovarian cancer." J. Clin. Oncol . 12 : 64-69 , 1994

Haupt, Y., Rowan, S., Shaulian, E., Vousden, K.H., and Oren, M ". Induction of apoptosis in HeLa cells by trans-activation-deficient p53" . Genes Dev . 9 : 2170-2183 , 1995

Haupt, Y. and Oren, M. "p53-mediated apoptosis: mechanisms and regulation" . Behring Inst. Mitt . 97: 32-59 , 1996

Haupt, Y., Maya, R., Kazaz, A., and Oren, M . "Mdm2 promotes the rapid degradation of p53." Nature 397 : 296-299 , 1997

Helland, A., Langerod, A., Johnsen, H., Olsen, O.A., Skovlund, E., and Borresen-Dale, A.-L. "p53 polymorphism and risk of cervical carcinoma" . Nature 396: 530-531 , 1998

Henriksen, R., and Oberg, K ". p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry." Gynecol. Oncol . 53(3): 301-306 , 1994

Hermeking, H., Lengauer, C., Polyak, K., He, T.C., Zhang, L., Thiagalingam, S., Kinzler, K.W., and Vogelstein, B. "14-3-3 sigma is a p53-regulated inhibitor of G2/M progression." Mol. Cell 1 : 3-11 , 1997


Herod, J., Eliopoulos, A., Warwick, J., Niedobitek, G., Young, L., and Kerr, D. "The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma." Cancer Res . 56 : 2178-2184 , 1996

Hildesheim, A., Schiffman, M., Brinton, L.A., Fraumeni, J.F., Herrero, R., Bratti, M.-C., Schwartz, P., Mortel, R., Barnes, W., Greenberg, M., McGowen, L., Scott, D.R., Martin, M., Herrera, J.E., and Carrington, M. "P53 polymorphism and risk of cervical carcinoma" . Nature 396 : 530-531 , 1998

Hirai, M., Kelsey, L.S., Maneval, D.C., Vaillancourt, M., and Talmadge, J.E ". Adenovirus p53 purging for human breast cancer stem cell products" . Acta Haematol . 101 : 97-105, 1999

Holschneider, C.H., and Berek, J.S. "Ovarian Cancer: Epidemiology, Biology, and Prognostic Factors" . Sem. Surg. Oncol . 19: 3-10 , 2000

Hollstein, M., Rice, K., Greenblatt, M.S., Soussi, T., Fuchs, R., Sorlie, T., Hovig, E., Smith-Sorensen, B., Montesano, R., and Harris, C.C. "Database of p53 gene somatic mutations in human tumors and cell lines" . Nucleic Acids Res . 22: 3551-3555, 1994

Howes, K.A., Ransom, N., Papermaster, D.S., Lasudry, J.G.H., Albert, D.M., and Windle, J.J. "Apoptosis or retinoblastoma: Alternative fates of phosphoreceptors expressing the HPV-16 E7 gene in the presence or absence of p53" . Genes Dev . 8: 1300-1310, 1994

Hsieh, J.-K., Chan, F.S.G., O‘Connor, D.J., Mittnacht, S., Zhong, S., and Lu, X. "RB regulates the stability and the apoptotic function of p53 via MDM2." Mol. Cell 3: 181-193, 1999

Ikenberg, H., Matthay, K., Schmitt, B., Bauknecht, T., Kiechle-Schwarz, M., Göppinger, A., and Pfleiderer, A. "p53 Mutation and MDM2 amplification are rare even in Human Papillomavirus- negative cervical carcinomas" . Cancer 76: 57-66, 1995

Inoue, M., Fujita, M., Enomoto, T., Morimoto, H., Monden, T., Shimano, T., and Tanizawa, O. "Immunohistochemical analysis of p53 in gynecologic tumors." Am. J. Clin. Pathol . 102 (5): 665-670 , 1994

Israeli, D., Tessler, E., Haupt, Y., Elkeles, A., Wilder, S., Amson, R., Telerman, A., and Oren, M.A ". Novel p53-inducible gene PAG608, encodes a nuclear zinc finger protein whose overexpression promotes apoptosis" . EMBO J . 16: 4384-4392 , 1997

Ito, T., Seyama, T., Hayashi, T.E.A. "Hae III polymorphism in intron 1 of the human p53 gene. " Hum. Genet . 92, 222- , 1994

Jacobs, I.J., Kohler, M.F., Wiseman, R.W., Marks, J.R., Whitaker, R., Kerns, B.A.J., Humphrey, P., Berchuck, A., Ponder, B.A.J., and Bast, R.C. Jr. "Clonal origin of epithelial ovarian carcinoma: Analysis by Loss of Heterozygosity, p53 mutation, and x-chromosome inactivation" . J. Natl. Cancer Inst . 84: 1793-1798 , 1992

Jones, S.N., Roe, A.E., Donehower, L.A., and Bradley, A. "Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53" . Nature 378 : 206-208 , 1995


Josefsson, A.M., Magnusson, P.K.E., Ylitalo, N., Quarforth-Tubbin, P., Ponten, J., Adami, H.O., and Gyllensten, U.B . "P53 polymorphism and risk of cervical carcinoma." Nature 396 : 530-531 , 1998

Kanamori, Y., Kigawa, J., Minagawa, Y., Irie, T., Oishi, T., Shimada, M., Takahashi, M., Nakamura, T., Sato, K., Terakawa, N ". A newly developed adenovirus-mediated transfer of a wild-type p53 gene increases sensitivity to cis-diamminedichloroplatinum (II) in p53-deleted ovarian cancer cells." Eur. J. Cancer 34: 1802-1806 , 1998

Kaplan, E.L., and Meier, P . "Nonparametric estimation from incomplete observations. J." Am. Stat. Assoc. 53, 457-481 , 1958

Kappes, S., Milde-Langosch, K., Kressin, P., Passlack, B., Dockhorn-Dworniczak, B., Rohlke, P., and Loning, T. "p53 mutations in ovarian tumors, detected by temperature-gradient gel electrophoresis, direct sequencing and immunohistochemistry." Int. J. Cancer 64: 52-59 , 1995

Kastan, M., Zhan, Q., el-Deiry, W., Carrier, F., Jacks, T., Walsh, W., Plunkett, B., Vogelstein, B., and Fornace, A.J ". A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-teleangiectasia." Cell 71: 587-597 , 1992

Kihana, T., Tsuda, H., Teshima, S., Okada, S., Matsuura, S., and Hiroshashi, S. "High incidence of p53 gene mutation in human ovarian cancer and its association with nuclear accumulation of p53 protein and tumor DNA aneuploidy." Jpn. J. Cancer Res. 83 : 978-984 , 1992

Kim, J.W., Cho, Y.H., Kwon, D.J., Kim, T.E., Park, T.C., Lee, J.M., and Namkoong, S.E. "Aberrations of the p53 tumor suppressor gene in human epithelial ovarian carcinoma. " Gynecol. Oncol . 57 : 199-204 , 1995

Kim, J., Hwang, E.S., Kim, J.S., You, E.H., Lee, S.H., and Lee, J.H . "Intraperitoneal therapy with adenoviral-mediated p53 tumor suppressor gene for ovarian cancer model in nude mouse." Cancer Gene Ther . 6 : 172-178 , 1999

Kiyokawa, T. "Alteration of p53 in ovarian cancer: Its occurence and maintenance in tumor progression" . J. Gynecol. Pathol . 13: 311-318 , 1994

Klemi, P., Pylkkanen, L., Kiilholma, P., Kuruvinen, K., and Joensuu, H . "p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma" . Cancer 76(7): 1201-1208 , 1995

Ko, J.L., Cheng, Y.W., Chang, S.L., Su, J.M., Chen, C.Y., and Lee, H. "MDM2 mRNA expression is a favorable prognostic factor in non-small-cell lung cancer." Int. J. Cancer 89 : 265-270, 2000

Kohler, M., Marks, J., Wiseman, R., Jacobs, I., Davidoff, A., Clarke-Pearson, D., Soper, J., Bast, R., and Berchuck, A. "Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer" . J. Natl. Cancer Inst . 85(18): 1513-1519 , 1993a

Kohler, M., Kerns, B., and Berchuck, A. "Mutation and overexpression of p53 in early stage epithelial ovarian cancer" . Obstet. Gynecol . 81 : 643-650, 1993b


Kondo, S., Barnett, G.H., Hara, H., Morimura, T., and Takeuchi, J. "MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis" . Oncogene 10: 2001-2006 , 1995

Kosary, C.L. "FIGO stage, Histology, Histologic Grade, Age and Race as Prognostic Fcators in Determining Survival for Cancers of the Female Gynecological System: An Analysis of 1973-1987 SEER Cases of Cancers of the Endometrium, Cervix, Ovary, Vulva and Vagina." Sem. Surg. Oncol . 10: 31-46 , 1994

Kraus, A., Neff, F., Behn, M., Schuermann, M., Muenkel, K., and Schlegel, J. "Expression of alternatively spliced mdm2 transcripts correlates with stabilized wild-type p53 protein in human glioblastoma cells. " Int. J. Cancer 80: 930-934 , 1999

Kubbutat, M., Jones, S., and Vousden, K. "Regulation of p53 stability by mdm2. " Nature 387: 299-303 , 1997

Kubbutat, M., and Vousden, K.H . "Keeping an old friend under control: regulation of p53 stability" . Mol. Med. Today 4 : 250-256 , 1998

Kubbutat, M.H.G., Ludwig, R.L., Levine, A.J., and Vousden, K.H . "Analysis of the degradation function of Mdm2." Cell Growth Diff . 10: 87-92 , 1999

Kupryjanczyk, J., Thor, A., Beauchamp, R., Merritt, V., Edgerton, S., Bell, D., and Yandell, D. "p53 gene mutations and protein accumulation in human ovarian cancer. Proc" . Natl. Acad. Sci . USA 90: 4961-4965, 1993

Kupryjanczyk, J., Bell, D., Dimeo, D., Yandell, D., Scully, R., and Thor, A ". p53 expression in ovarian borderline tumors and stage I carcinomas" . Am. J. Clin. Pathol . 102(5): 671-676, 1994

Kupryjanczyk, J., Bell, D., Dimeo, D., Beauchamp, R., Thor, A., and Yandell, D. "p53 gene analysis of ovarian borderline tumors and stage I carcinomas." Human Pathol . 26: 387-392 , 1995

Kurman, R.J. "(Editor) Blaustein‘s Pathology of the Female Genital Tract. 3rd edition." Springer-Verlag New York-Berlin-Heidelberg-London-Paris-Tokyo 1987 page 560-505

Kussie, P.H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A.J., and Pavletich, N.P. "Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain." Science 274: 948-953, 1996

Laemmli, U.K ". Cleavage of structural proteins during the assembly of the head of bacteriophage T4" . Nature 227: 680-685 , 1970

Lancaster, J.M., Brownlee, H.A., Wiseman, R.W., and Taylor, J . "p53 polymorphism in ovarian and bladder cancer" . Lancet 182: 346 , 1995

Landers, J., Haines, D., Strauss III J., and George, D . "Enhanced translation: A novel mechanism of mdm2 oncogene overexpression identified in human tumor cells." Oncogene 9: 2745-2750, 1994


Landers, J.E., Cassel, S.L., and George, D.L. "Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein" . Cancer Res . 57 : 3562-3568, 1997

Landis, S.H., Murray, T., Bolden, S., and Wingo, P.A. "Cancer Statistics 1998" . CA Cancer J. Clin . 48 : 6 - 29 , 1998

Lane, D.P. "p53, guardian of the genome" . Nature 358 : 15-16, 1992

Lanham, S., Campbell, I., Watt, P., and Gornall, R. "P53 polymorphism and risk of cervical cancer. " Lancet 352: 1631 , 1998

Laplace-Marieze, V., Presncau, N., Sylvain, V., Kwiatkowski, F., Lortholary, A., Hardouin, A., and Bignon, Y.J . "Systematic sequencing of the BRCA-1 coding region for germ-line mutation detection in 70 French high risk families" . Int. J. Oncol . 14 : 971-977 , 1999

Lausen, B., and Schumacher, M. Maximally selected rank statistics. Biometrics 48: 73-86, 1992

Lazar, V., Hazard, F., Bertin, F., Janin, N., Bellet, D., and Bressac, B . "Simple sequence repeat polymorphism within the p53 gene" . Oncogene 8: 1703-1705 , 1993

Lee, J., Kang, Y., Park, S., Kim, B., Lee, E., Lee, K., Kavanagh, J., and Wharton, J ". p53 mutation in epithelial ovarian carcinoma and borderline ovarian tumor." Cancer Genet. Cytogenet . 85 : 43-50 , 1995

Lee, S., Elenbaas, B., Levine, A., and Griffith, J. "p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches." Cell 81: 1013-1020 , 1995

Leng, P., Brown, D.R., Shivakumar, C.V., Deb, S., and Deb, S.P . "N-terminal 130 amino acids of MDM2 are sufficient to inhibit p53-mediated transcriptional activation." Oncogene 10 : 1275-1282 , 1995

Levesque, M., Katsaros, D., Yu, H., Zola, P., Sismondi, P., Giardina, G., and Diamandis, E. "Mutant p53 portein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma" . Cancer 75: 1327-1338 , 1995

Levine, A.J . "p53, the cellular gatekeeper for growth and devision." Cell 88: 323-331 , 1997

Levkau, B., Koyama, H., Raines, E.W., Clurman, B.E., Herren, B., Orth, K., and Ross, J.M.R.R . "Cleavage of p21cip1/waf1 and p27kip1 mediates apoptosis in endothelial cells through activation of cdk2: role of a caspase cascade." Mol. Cell 1 :553-563, 1998

Lewin, B. Genes V. Oxford University Press Inc ., New York , 688-689 , 1994

Li, F.P., and Fraumeni, J.F. "Jr. Soft-tissue sarcoma, breast cancer, and other neoplasms. A familial syndrome?" Ann. Intern. Med . 71: 747-752 , 1969

Lin, P.M., Liu, T.C., Chang, J.G., Chen, T.P., and Lin, S.F ". Aberrant TSG101 transcripts in acute myeloid leukemia." Br.J. Haematol. 102: 753-758 , 1998


Lin, Y., Ma, W., and Benchimol, S. "Pidd, a new death-domain-containing protein, is induced by p53 and promotes apoptosis." Nature Gen . 26: 124-127 , 2000

Linke, S., Clarkin, K., DiLeonardo, A., Tsou, A., and Wahl, G ". A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. " Genes Dev . 10: 934-937 , 1996

Lowe, S.W., Ruley, H.E., Jacks, T., and Housman, E. "p53-dependent apoptosis modulates the cytotoxicity of anticancer agents." Cell 74: 957-967 , 1993

Lowe, S.W., Bodis, S., McClatchey, A., Remington, L., Ruley, H.E., Fisher, D.E., Housman, D.E., and Jacks, T. "p53 status and the efficacy of cancer therapy in vivo" . Science 266: 807-810 1994

Lu, H., Fisher, R.P., Bailey, P., and Levine, A.J. "The CDK7-cycH-p36 complex of transcription factor IIH phosphorylates p53, enhancing its sequence-specific DNA binding activity in vitro." Mol. Cell. Biol . 17: 5923-5934, 1997

Lu, W., Pochampally, R., Chen, L., Traidej, M., Wang, Y., and Chen, J. "Nuclear exclusion of p53 in a subset of tumors requires MDM2 function" . Oncogene 19 : 232-240 , 2000

Lukas, J., Groshen, S., Saffari, B., Niu, N., Reles, A., Wen, H.-W., Felix, J., Jones, L.A., Hall, F.L., and Press, M.F ". WAF1/CIP1 Gene polymorphism and expression in carcinomas of the breast, ovary, and endometrium." Am. J. Pathol. 150: 167-175, 1997

Lund, B., Hansen, O.P., Theilade, K., Hansen, M., and Nejit, J.P. "Phase II study of gemcitabine (2.2-difluorodeoxycytidine) in previously treated ovarian cancer patients." J. Natl. Cancer Inst. 86: 152- 156, 1994

Lynch, H.T., Harris, R.E., Guirgis, H.A., Maloney, K., Carmody, L.L., and Lynch, J.F. "Familial association of breast/ovarian carcinoma" . Cancer 41: 1543-1549, 1978

Mackett, M., Smith, G.L., and Moss, B. "Vaccinia Virus: A selectable eukaryotic cloning and expression vector. " Proc. Natl. Acad. Sci . USA 79: 7415-7419 , 1982

Makar, A.P., Baekelandt, M., Tropé, C.G., and Kristensen, G.B. "The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer" . Gynecol. Oncol . 56: 175-180, 1995

Maki, C.G., and Howley, P.M . "Ubiquination of p53 and p21 is differentially affected by ionizing and UV radiation." Mol. Cell. Biol . 17 : 355-363 , 1997

Makni, H., Franco, E.L., Kaiano, J., Villa, L.L., Labrecque, S., Dudley, R., Storey, A., and Matlashewski, G.J ". P53 polymorphism in codon 72 and risk of human papilloma-induced cervical cancer: effect of inter-laboratory variation" . Int. J. Cancer 87: 528-533 , 2000

Mantel, N., and Haenszel, W. "Statistical aspects of the analysis of data from retrospective studies of disease" . J. Natl. Cancer Inst . 22: 719-748, 1959


Marchetti, A., Buttitta, F., Girlando, S., Palma, P.D., Pellegrini, S., Fina, P., Doglioni, C., Bevilacqua, G., and Barbareschi, M . "mdm2 gene alterations and mdm2 protein expression in breast carcinomas." J. Pathol . 175: 31-38 , 1995a

Marchetti, A., Buttitta, F., Pellegrini, S., Giorgio, M., Chella, A., Angeletti, C.A., and Bevilacqua, G ". mdm2 gene amplification and overexpression in non-small cell lung carcinomas with accumulation of the p53 protein in the absence of p53 gene mutations. Diagn." Mol. Pathol . 4: 93- 97, 1995b

Marechal, V., Elenbaas, B., Taneyhill, L., Piette, J., Mechali, M., Nicolas, J.-C., Levine, A.J., and Moreau, J ". Conservation of structural domains and biochemical activities of the MDM2 protein from Xenopus laevis." Oncogene 14: 1427-1433 , 1997

Marin, C.M., Jost, C.A., Brooks, L.A., Irwin, M.S., O'Nions, J., Tidy, J.A., James, N., McGregor, J.M., Harwood, C.A., Yulug, I.G., Vousden, K.H., Allday, M.J., Gusterson, B., Ikawa, S., Hinds, P.W., Crook, T., and Kaelin, W.G. "A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. " Nature Gen. 25: 47-54 , 2000

Markman, M., Rothman, R., Hakes, T., Reichman, B., Hoskins, W., Rubin, S., Jones, Walmadrones, L., and Lewis, J.L .Jr . "Second-line platinum-therapy in patients with ovarian cancer previously treated with cisplatin." J. Clin. Oncol . 9 : 389-393 , 1991

Marks, J., Davidoff, A., Kerns, B., Humphrey, P., Pence, J., Dodge, R., Clarke-Pearson, D., Iglehart, J., Bast, R., and Berchuck, A ". Overexpression and mutation of P53 in epithelial ovarian cancer" . Cancer Res . 52 : 2979-2984 , 1991

Marx, D., Meden, H., Ziemck, T., Lenthe, T., Kuhn, W., and Schauer, A ". Expression of the p53 tumor suppressor gene as a prognostic marker in platinum-treated patients with ovarian cancer" . Eur. J. Cancer 34: 845-850 , 1998

Matlashewski, G., Lamb, P., Pim, D., Peacok, J., Crawford, L., and Benchimol, S. "Isolation and charcterization of a human p53 cDNA clone: expression of the human p53" . EMBO J . 3: 3257-3262 , 1984

Matlashewski, G.J., Tuck, S., Pim, D., Lamb, J., Schneider, J., and Crawford, L.V. "Primary structure polymorphism at amino acid residue 72 of human p53. Mol." Cell. Biol . 7: 961-963 , 1987

Matsumoto, R., Tada, M., Nozaki, M., Zhang, C.L., Sawamura, Y., and Abe, H ". Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms. " Cancer Res . 58: 609-613 , 1998

Mavridou, D., Gornall, R., Campbell, I.G., and Eccles, D.M. "TP53 intron 6 polymorphism and the risk of ovarian and breast cancer." Br. J. Cancer 77: 676-678, 1998

Mazars, R., Pujol, P., Maudelonde, T., Jeanteur, P., and Theillet, C. "p53 mutations in ovarian cancer: A late event ?" Oncogene 6: 1685-1690 , 1991

Maxwell, S. "Selective Compartmentalization of Different mdm2 Proteins within the Nucleus" . Anticancer Res . 14: 2541-2548 , 1994


May, P., and May, E. "Twenty years of p53 research: structural and functional aspects of the p53 protein. " Oncogene 18: 7621-7636 , 1999

McCann, A., Kirley, A., Carney, D., Corbally, N., Magee, H., Keating, G., and Dervan, P. "Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status" . Br. J. Cancer 71 : 981-985 , 1995

McGuire, W.P., Hoskins, W.J., Brady, M.F., Kucera, P.R., Partridge, E.E., Look, K.Y., Clarke-Pearson, D.L., and Davidson, M. "Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer" . New Engl . J. Med . 334 : 1-6 , 1996

McGuire, W.P., and Ozols, R.F . "Chemotherapy of advanced ovarian cancer." Semin. Oncol . 25: 340-348 , 1998

Meden, H., Marx, D., Rath, W., Kron, M., Fattahi-Meibodi, A., Hinney, B., Kuhn, W., and Schauer, A. "Overexpression of the oncogene c-erbB2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression" . Int. J. Gynecol. Pathol . 13 : 45-53, 1994

Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P.A., Harshman, K., Tartigian, S., Lin, Q., Cochran, C., Bennett, L.M., and Ding, W. A "strong candidate for the breast ovarian cancer susceptibility gene BRCA1" . Science 266: 66-71 , 1994

Miller, R., and Siegmund, D ". Maximally selected chi square statistics" . Biometrics 38: 1011-1016, 1982

Milner, B., Allan, L., Eccles, D., Kitchener, H., Leonard, R., Kelly, K., Parkin, D., and Haites, N ". p53 gene mutation is a common genetic event in ovarian carcinoma" . Cancer Res . 53: 2128-32 , 1993

Miyashita, T., Krajewski, S., Krajewska, M., Wang, H., Liebermann, D., Hoffman, B., and Reed, J.C. "Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo." Oncogene 9 : 1799-1805 , 1994

Miyashita, T., and Reed, J. "Tumor suppressor p53 is a direct transcriptional activator of the human bax gene" . Cell 80: 293-299 , 1995

Moll, U., LaQuaglia, J., Benard, J., and Riou, G. "Wild-type p53 undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in undifferentiated tumors. " Proc. Natl. Acad. Sci . USA 92: 4407-4411 , 1995

Mok, S., Lo, K., and Taso, S . "Direct cycle sequencing of mutated alleles detected by PCR single-strand conformation polymorphism analysis" . Biotechniques 14 (5): 790-794, 1993

Momand, J., Zambetti, G., Olson, D., George, D., and Levine, A. "The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53 mediated" "transactivation." Cell 69 : 1237-1245 , 1992

Momand, J. and Zambetti, G. "Mdm-2: „Big Brother„ of p53" . J. Cell. Biochem . 64: 343-352, 1997


Montes de Oca Luna, R., Tabor, A.D., Eberspaecher, H., Hulboy, D.L., Worth, L.L., Colman, M.S., Finlay, C.A., and Lozano, G. "The organization and expression of the mdm2 Gene" . Genomics 33: 352-357 , 1996

Morgenbesser, S.D., Williams, B.O., Jacks, T., and DePinho, R.A. "p53 dependent apoptosis produced by Rb-deficiency in the developing mouse lens" . Nature 371 : 72-74 , 1994

Moss, B., and Flexner, C. "Vaccinia virus expression vectors." Annu. Rev . Immunol . 5: 305 -324 , 1987

Mujoo, K., Maneval, D.C., Anderson, S.C., and Gutterman, J.U. "Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma" . Oncogene 12: 1617-1623 , 1996

Nagata, S . "Apoptosis by death factor" . Cell 88: 355-365 , 1997

Narod, S.A., Risch, H., Moslehi, R., Dorum, A., Neuhausen, S., Olsson, H., Provencher, D., Radice, P., Evans, G., Bishop, S., Brunet, J.-S., and Ponder, A.J. "Oral contraceptives and the risk of hereditary ovarian cancer. " N. Engl . J. Med . 339 : 424-428 , 1998

Negrini, M., Monaco, C., Vorechovsky, I., Ohta, M., Druck, T., Baffa, R., Huebner, K., and Croce, C. "The FHIT gene at 3p14.2 is abnormal in breast carcinomas." Cancer Res. 56: 3173-3179, 1996

Nielsen, L.L., and Maneval, D ". p53 tumor suppressor gene therapy for cancer" . Cancer Gene Ther . 5: 52-63 , 1998

Nielsen, L.L., Lipari, P., Dell, J. Gurnani, M., and Hajian, G ". Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate and breast cancer" . Clin. Cancer Res . 4: 835-846, 1998

Niwa, K., Itoh, M., Murase, T., Itoh, N., Mori, H., and Tamaya, T ". Alteration of p53 gene in ovarian carcinoma: Clinicopathological correlation and prognostic significance" . Br. J. Cancer 70: 1191-1197 , 1994

Oberosler, P., Hloch, P., Ramsperger, U., and Stahl, H. "p53-catalyzed annealing of complementary single-stranded nucleic acids" . EMBO J . 12: 2389-2396 , 1993

Ogawa, N., Fujiwara, T., Kagawa, S., Nishizaki, M., Morimoto, Y., Tanida, T., Hizuta, A., Yasuda, T., Roth, J.A., and Tanaka, N ". Novel combination therapy for human colon cancer with adenovirus-mediated wild-type p53 gene transfer and DNA-damaging chemotherapeutic agent" . Int. J. Cancer 73: 367-370 , 1997

Oliner, J., Kinzler, K., Meltzer, P., George, D., and Vogelstein, B. "Amplification of a gene encoding a p53-associated protein in human sarcomas." Nature 358: 80-83, 1992

Oliner, J., Pietenpol, J., Thiangalingam, S., Gyuris, J., Kinzler, K., and Vogelstein, B . "Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53" . Nature 362: 857-860, 1993


Olson, D.C., Marechal, V., Momand, J., Chen, J., Romocki, C., and Levine, A.J . "Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes." Oncogene 8: 2353-2360, 1993

Oltvai, Z.N., Milliman, C.L., and Korsmeyer, S.J ". Bcl-2 heterodimerizes in-vivo with a conserved homolog, bax, that accelerates programmed cell death" . Cell 74: 609-619, 1993

Palazzo, J.P., Monzon, F., Burke, M., Hyslop, T., Dunton, C., Barusevicius, A., Capuzzi, D., and Kovatich, A.J. "Overexpression of p21WAF1/CIP1 and MDM2 characterizes serous borderline ovarian tumors." Hum. Pathol . 31 : 698-704 , 2000

Panicali, D., and Paoletti, E. "Construction of poxviruses as cloning vectors: Insertion of the thymidine kinase gene from herpes simplex virus into the DANN of infectious vaccinis virus" . Proc. Natl. Acad. Sci . USA 79: 4927-4931 , 1982

Peller, S., Kopilova, Y., Slutzki, S., Halevy, A., Kvitko, K., and Rotter, V. "A novel polymorphism in intron 6 of the human p53 gene: A possible association with cancer predisposition and susceptibility." DNA Cell Biol . 14: 983-990, 1995

Perry, M.E., Mendrysa, S.M., Saucedo, L.J., Tannous, P., and Holubar, M . "p76 (MDM2) inhibits the ability of p90 (MDM2) to destabilize p53." J. Biol. Chem . 275: 5733-5738 , 2000

Pestell, K.E., Hobbs, S.M., Titley, J.C., Kelland, L.R., and Wlton, M.I . "Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line." Mol. Pharmocol. 57: 503-511 , 2000

Petru, E., Lahousen, M., Tamussino, K., Pickel, H., Stranzl, H., Stettner, H., and Winter, R. "Lymphadenectomy in stage I ovarian cancer" . Am. J. Obstet. Gynecol . 170: 656-662, 1994

Pettersson, F. "Annual report on the results of treatment in gynecologic cancer: statements of the results obtained in patients, 1982 to 1986, inclusive 3- and 5-year survival up to 1990." Int. J. Gynecol. Oncol . 21 (suppl.), 1991

Petty, R., Evans, A., Duncan, I., Kurbacher, C., and Cree, I. "Drug resistance in ovarian cancer - the role of p53. " Pathol. Oncol. Res . 4: 97-102, 1998

Picksley, S.M., Vojtesek, B., Sparks, A., and Lane, D . "Immunochemical analysis of the interaction of p53 with MDM2-fine mapping of the MDM2 binding site on p53 using synthetic peptides. " Oncogene 9: 2523-2529 , 1994

Piette, J., Neel, H., and Maréchal, V. Mdm2: keeping p53 under control. Oncogene 15: 1001-1010, 1997

Piver, M.S., Jishi, M.F., Tsukada, Y., and Nava, G ". Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Regitry." Cancer 71: 2751-2755 ,


Pleasants, L.M., and Hansen, M.F . "Identification of a polymorphism in intron 2 of the p53 gene. " Human Genetics 93: 607-608 , 1994

Polyak, K., Xia, Y., Zweier, J.L., Kinzler, K.W., and Vogelstein, B ". A model for p53 induced apoptosis" . Nature 389: 300-305 , 1997

Pomerantz, J., Schreiber-Agus, N., Liégeois, N.J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., Cordon-Cardo, C., and DePinho, R.A. "The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2‘s inhibition of p53." Cell 92: 713-723 , 1998

Prives, C . "How loops, beta sheets and alpha helices help us to understand p53" . Cell 78: 543-546 , 1994

Pützer, B.M ". The role of tumor suppressor gene therapy for anticancer treatment" . Tumordiagn. Ther. 21 : 1-7 , 2000

Qin, X.-Q., Livingston, D.M., Kaelin, W.G.Jr., and Adams, P.D . "Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis." Proc. Natl. Acad. Sci. USA 91: 10918-10922 , 1994

Quesnel, B., Preudhomme, C., Fournier, J., Fenaux, P., and Peyrat, J. "MDM2 gene amplification in human breast cancer" . Eur. J. Cancer 30A: 982-984 , 1994

Ralhan, R., Sandhya, A., Meera, M., Bohdan, W., and Nootan, S.K . "Induction of MDM2-P2 transcripts correlates with stabilized wild-type p53 in betel- and tobacco-related human oral cancer" . Am. J. Pathol. 157: 587-596, 2000

Reisman, D., and Loging, W.T . "Transcriptional regulation of the p53 tumor suppressor gene." Sem. Cancer Biol . 8: 317-324 , 1998

Reles, A., Schmider, A., Press, M.F., Schönborn, I., Friedmann, W., Huber-Schumacher, S., Strohmeyer, T., and Lichtenegger, W . "Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome. J. Cancer Res." Clin. Oncol . 122: 489-494 , 1996

Reles, A., Wein, U., Lichtenegger, W. "Transvaginal color Doppler sonography and conventional sonography in the preoperative assessment of adnexal masses. " J. Clin. Ultrasound 25: 217-225 , 1997

Reles, A., Wein, U., Lübke, M., Lichtenegger, W. "Transvaginale Farbdopplersonographie in der präoperativen Diagnostik von Adnextumoren. Diagnostische Wertigkeit im Vergleich zu konventionellen Sonographiekriterien" . Geb. Frauenheilk . 58: 93-99 , 1998

Reles, A.E., Gee, C., Schellschmidt, I., Schmider, A., Unger, M., Friedmann, W., Lichtenegger, W. , and Press, M.F . "Prognostic Significance of DNA Content and S-Phase Fraction in Epithelial Ovarian Carcinomas Analyzed by Image Cytometry." Gynecol. Oncol . 71: 3-13 , 1998

Reles, A., Wen, H.W., Schmider, A., Gee, C., Runnebaum, I.B., Kilian, U., Jones, L.A., El-Naggar, A., Minguillon, C., Schönborn, I., Reich, O., Kreienberg, R., Lichtenegger, W., Press, M.F. "Correlation of p53 mutations with resistance to platinum-based "


"chemotherapy and shortened survival in ovarian cancer." Clin. Cancer Res. in press, 2001

Righetti, S.C., Della Torre, G., Pilotti, S., Ménard, S., Ottone, F., Colnaghi, M.I., Pierotti, M.A., Lavarino, C., Cornarotti, M., Oriana, S., Böhm, S., Bresciani, G.L., Spatti, G., and Zunino, F. "A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. " Cancer Res. 56, 689-693 , 1996

Röhlke, P., Milde-Langosch, K., Weyland, C., Pichlmeier, U., Jonat, W., and Loning, T . "p53 is a persistent and predictive marker in advanced ovarian carcinomas: multivariate analysis including comparison with Ki67" Immunoreactivity. J. Cancer Res. Clin. Onco l. 123: 496-501 , 1997

Roth, J., Dobbelstein, M., Freedman, D.A., Shenk, T., and Levine, A.J ". Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein" . EMBO J . 17: 554-564 , 1998

de Rozieres, S., Maya, R., Oren, M. and Lozano, G. "The loss of mdm2 induces p53-mediated apoptosis" . Oncogene 19 : 1691-1697 , 2000

Runnebaum, I.B., Tong, X.W., König, R., Hong, Z., Körner, K., Atkinson, E.N., Kreienberg, R., and Kieback, D.G . "p53-based blood test for p53PIN3 and risk for sporadic ovarian cancer" . Lancet 345: 994, 1995

Sakaguchi, K., Herrera, J.E., Saito, S., Miki, T., Bustin, M., Vassilev, A., Anderson, C.W., and Appella, E ". DNA damage activates p53 through a phosphorylation-acetylation cascade" . Genes Dev . 12: 2831-2841 , 1998

Sakamoto, T., Nomura, N., Mori, H., and Wake, N. "Poor correlation with Loss of Heterozygosity on chromosome 17p and p53 mutations in ovarian cancers" . Gynecol. Oncol. 63: 173-179 , 1996

Sanger, F., Nicklen, S., and Coulson, A. "DNA sequencing with chain-terminating inhibitors. " Proc. Nat. Acad. Sci . 74: 5463-5467 , 1977

Santoro, I., and Groden, J ". Alternative splicing of the APC gene and ist association with terminal differentiation" . Cancer Res. 57 : 488-494 , 1997

Saucedo, L.J., Myers, C.D. and Perry, M.E . "Multiple Murine Double Minute Gene 2 (MDM2) proteins are induced by ultraviolet light." J. Biol. Chem . 274: 8161-8168 , 1999

Scambia, G., Masciullo, V., Benedetti-Panici, P., Marono, M., Ferrandino, G., Todaro, N., Bellacosa, A., Jain, S.K., Neri, O., Pifanelli, A., and Mancuso, S. "Prognostic significance of ras/p21 alterations in human ovarian cancer" . Br. J. Cancer 75: 1547-1553 , 1997

Schmider, A. "Immunhistochemische Bestimmung der Überexpression des Tumorsuppressor-gens p53, seines Mediatorgens WAF1/CIP1 und des Onkogens c-neu beim Ovarialkarzinom, unter besonderer Berücksichtigung der Alterationen des p53 Tumorsuppressorgens" . Diss., Berlin, p . 95-99, 1999


Schmider, A., Gee, C., Friedmann, W., Lukas, J.J., Press, M.F., Lichtenegger, W., and Reles, A ". p21 (WAF1/CIP1) Protein Expression Is Associated with Prolonged Survival but not with p53 Expression in Epithelial Ovarian Carcinoma. " Gynecol. Oncol . 77: 237-242 , 2000

Schuyer, M., Henzen-Logmans, S.C., van der Burg, M.E.L., Fieret, E.J.H., Klijn, J.G.M., Foekens, J.A., and Berns, E.M.J.J. "High prevalence of codon 213ARGrarrSTOP mutations of the TP53 gene in human ovarian cancer in the southwestern part of the Netherlands" . Int. J. Cancer 5: 65-68 , 1998

Schwartz, D., and Rotter V. "p53-dependent cell cycle control: response to genotoxic stress. Sem" . Cancer Biol . 8: 325-336 , 1998

Scully, R.E. "Tumors of the ovary and maldeveloped gonads. Atlas of Tumor Pathology, 2nd series, fascicle 16. Washington, DC, Armed Forces Institute of Pathology, " 1979

Sheridan, E., Silcocks, P., Hancock, B., and Goyns, M . "P53 mutation in a series of epithelial ovarian cancers from the U.K. and its prognostic significance" . Eur. J. Cancer 11 : 1701-1704 , 1994

Shieh, S.Y., Ikeda, M., Taya, Y., and Prives, C . "DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2" . Cell 91: 325-334 , 1997

Shieh, S.-Y., Taya, Y., and Prives, C ". DNA.damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization. EMBO J." 18: 1815-1823, 1999

Siddik, Z.H., Mims, B., Lozano, G., and Thai, G ". Independent pathways of p53 induction by Cisplatin and X-Rays in a Cisplatin-resistant Ovarian Tumor Cell Line. " Cancer Res. 58: 698-703 ,1998

Sigalas, I., Calvert, A., Anderson, J., Neal, D., and Lunec, J ". Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer." Nature Med. 2: 912-917 , 1996

Siliciano, J.D., Canman, C.E., Taya, Y., Sakaguchi, K., Appella, E., and Kastan, M.B. "DNA damage induces phophorylation of the amino terminus of p53" . Genes Dev. 11 : 3471-3481 , 1997

Skilling, J., Sood, A., Niemann, T., Lager, D., and Buller, R ". An abundance of p53 null mutations in ovarian carcinoma." Oncogene 13: 117-123, 1996

Skomedal, H., Kristensen, G.B., Abeler, V.M., Borresen-Dale, A.-L., Tropé, C., and Holm, R . "TP 53 protein accumulation and gene mutation in relation to overexpression of mdm2 protein in ovarian borderline tumours and stage I carcinomas" . J. Pathol . 181: 158-165, 1997

Själander, A., Birgander, R., Kivelä, A., and Beckman, G ". p53 polymorphisms and haplotypes in different ethnic groups." Hum. Hered . 45: 144-149, 1995

Själander, A., Birgander, R., Hallmans, G., Cajander, S., Lenner, P., Athlin, L., Beckman, G., and Beckman, "L. p53 polymorphisms and haplotypes in breast cancer." Carcinogenesis 17: 1313-1316 , 1996


Slamon, D.J., Godolphin, W., Jones, L.A., Holt, J.A., Wong, S.G., Keith, D.E., Levin, W.J., Stuart, S.G., Udove, J., and Ullrich, A. "Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer" . Science 244: 707-712 , 1989

Slatko, B. "Thermal cycle dideoxy DNA sequencing. Methods" Mol. Biol. 58: 413-423, 1996

Slebos, R.J., Lee, M.H., Plunkett, B.S., Kessis, T.D., Williams, B.O., Jacks, T., Hedrick, L., Koston, M.B., and Cho, K.R. "p53-dependant G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16E7 oncoprotein" . Proc. Natl. Acad. Sci. USA 91 : 5320-5324 , 1994

Smith, M.L., Chen, I.-T., Zhan, Q., Bae, I., Chen, C.-Y., Gilmer, T.M., Kastan, M.B., O´Connor, P.M., and Fornace, A.J.Jr . "Interaction of the p53-regulated protein GADD45 with proliferating cell nuclear antigen" . Science 266: 1376-1380 , 1994

Song, K., Li, Z., Seth, P., Cowan, K.H., and Sinha, B.K . "Sensitization of cis-Platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human" "ovarian carcinomas" . Oncology Res . 9: 603-609 , 1997

Sood, A.K., Skilling, J.S., and Buller, R.E . "Ovarian cancer genomic instability correlates with p53 frameshift mutations." Cancer Res . 57: 1047-1049 , 1997

Soussi, T., Caron de Fromentel, C., and May, E. "Structural aspects of the p53 protein in relation to gene evolution." Oncogene 5: 945-952 , 1990

Soussi, T., and May, P. "Structural aspects of the p53 protein in relation to gene evolution: A second look." J. Mol. Biol . 260 : 623-637 , 1996

Spinardi, L., Mazars, R., and Theillet, C . "Protocols for an improved detection of point mutations by SSCP." Nucleic Acids Research 19 (14): 4009, 1991

Stewart, N., Hicks, G.G., Paraskevas, F., and Mowat, M ". Evidence for a second cell cycle block at G2/M by p53. " Oncogene 10: 109-115, 1994

Stommel, J.M., Marchenko, N.D., Jimenez, G.S., Moll, U.M., Hope, T.J., and Wahl, G.M. "A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking." EMBO J. 18: 1660-1672, 1999

Storey, A., Thomas, M., Kalita, A., Harwood, C., Gardiol, D., Mantovani, F., Breuers, J., Leigh, I.M., Matlashewski, G., and Banks, L ". Role of p53 polymorphism in the development of human papilloma-virus-associated cancer." Nature 393: 229-234, 1998

Suh, S.I., Cho, J.W., Baek, W.K., Suh, M.H., Carson, D.A ". Lack of mutation at p16INK4A gene but expression of aberrant p16INK4A RNA transcripts in human ovarian carcinoma. " Cancer Lett . 153: 175-182 , 2000

Tanner, B., Hengstler, J.G., Laubscher, S., Meinert, R., Oesch, F., Weikel, W., Knapstein, P.G., and Becker, R. "mdm2 mRNA expression is associated with survival in ovarian cancer. " Int. J. Cancer 74: 438-442 , 1997

Tao, W.K. and Levine A.J . "P19 (ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2." Proc.Natl. Acad. Sci . USA, 96: 6937-6941 , 1999


Taubert, H., Koehler, T., Meye, A., Bartel, F., Lautenschläger, C., Borchert, S., Bache, M., Schmidt, H., and Wurl, P ". mdm2 mRNA level is a prognostc factor in soft tissue sarcoma." Mol. Med . 6 : 50-59 , 2000

Teneriello, M., Ebina, M., Linnoila, R., Henry, M., Nash, J., Park, R., and Birrer, M. "p53 and Ki-ras gene mutations in epithelial ovarian neoplasms" . Cancer Res . 53: 3103-3108, 1993

Thut, C.J., Goodrich, J.A., and Tjian, R. "Repression of p53-mediated transcription by MDM2: a dual mechanism" . Genes Dev . 11: 1974-1986 , 1997

Tortolero-Luna, G., Follen Mitchell, M., and Rhodes-Morris, H.E. "Epidemiology and screening of ovarian cancer" . Obstet. Gynecol. Clin. North. Am . 21 : 1-23 , 1994

Tran, H., Gordenin, D., and Resnick, M. "The prevention of repeat-associated deletions in saccharomyces cerevisiae by mismatch repair depends on size and origin of deletions." Genetics 143: 1579-1587 , 1996

Unger, T., Juven-Gershon, T., Moallem, E., Berger, M., Sionov, R.V., Lozano, G., Oren, M., and Haupt, Y. "Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2" . EMBO J. 18: 1805-1814 , 1999

Utrera, R., Collavin, L., Lazarevic, D., Delia, D., and Schneider, C. "A novel p53 inducible gene coding for a microtubule-localized protein with G2-phase-specific expression." EMBO J. 17 : 5015-5025 , 1998

Vasey, P.A., Jones, N.A., Jenkins, S., Dive, C., and Brown, R. "Cisplatin, Camptothecin, and Taxol sensitivities of cells with p53-associated multidrug resistance" . Mol. Pharmakol. 50: 1536-1540 , 1996

Veldhoen, N., Metcalfe, S., and Milner, J. "A novel exon within the mdm2 gene modulates translation initiation in vitro and disrupts the p53-binding domain of mdm2 protein" . Oncogene 18 : 7026-7033 , 1999

Verselis, S.J., Li, F.P ". Common polymorphism in p53 intron" 2, IVS2+38G>C . Hum. Mutat. 16: 181 , 2000

Viale, G., Maisonneuve, P., Bonoldi, E., Di Bacco, A., Bevilacqua, P., Panizzoni, A., Radaelli, U., and Gasparini, G. "The combined evaluation of p53 accumulation and of Ki-67 (MIB1) labelling index provides independent information on overall survival of ovarian carcinoma patients" . Annals Oncol . 8 : 469-476, 1997

Vikhanskaya, F., Clerico, L., Valenti, M., Stanzione, M.S., Broggini, M., Parodi, S., and Russo, P. "Mechanism of resistance to Cisplatin in a human ovarian-carcinoma cell line selected for resistance to Doxorubicin: possible role of p53" . Int. J. Cancer 72 : 155-159, 1997

Vikhanskaya, F., Vignati, S., Beccaglia, P., Ottoboni, C., Russo, P., D‘Incalci, M., and Broggini, M . "Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to Paclitaxel by inducing G2/M Arrest and Apoptosis." Exp. Cell Res . 241: 96-101 , 1998


Virgilio, L., Shuster, M., Gollin, S., Veronese, M., Ohta, M., Huebner, K., and Croce, C ". FHIT gene alterations in head and neck squamous cell carcinomas" . Proc. Natl. Acad. Sci. USA 93 : 9770-9775 , 1996

Vogelstein, B ". Clinical implication of basic research: Cancer therapy meets p53" . New Engl . J. Med . 331 : 49-50 , 1994

Wahl, A.F., Donaldson, K.L., Fairchild, C., Lee, F.Y.F., Foster, S.A., Demers, G.W., and Galloway, D.A. "Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis" . Nature Med . 2 : 72-79 , 1996

Waldmann, T., Kinzler, K.W., and Vogelstein, B. "p21 is necessary for the p53-mediated G1 arrest in human cancer cells" . Cancer Res . 55 : 5187-5190 , 1995

Wang, P. Reed, M., Wang, Y., Mayr, G., Stenger, J.E., Anderson, M.E., Schwedes, J.F., and Tegtmeyer, P . "p53 domains: structure, oligomerization, and transformation" . Mol. Cell. Biol. 14 , 5182-5191 , 1994

Waterman, M.J.F., Stravridi, E.S., Waterman, J.L.F., and Halazonetis, T.D ". ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. " Nature Genet . 19 : 175-178, 1998

Wang, H., Zeng, X., Oliver, P., Le, L.P., Chen, J., Chen, L., Zhou, W., Agrawal, S., and Zhang, R. "MDM2 oncogene as a target for cancer therapy: An antisense approach. " Int. J. Oncol . 15 : 653-660 , 1999

Wang, X.W., Yeh, H., Schaeffer, L., Roy, R., Moncollin, V., Egly, J.-M., Wang, Z., Friedberg, E.C., Evans, M.K., Taffe, B.G., Bohr, V.A., Weeda, G., Hoeijmakers, J.H.J., Forrester, K., and Harris, C ". p53 modulation of TFIIH-associated nucleotide excision repair activity" . Nature Gen . 10: 188-195 , 1995

Wang, X.W., Vermeulen, W., Courson, J.D., Gibson, M., Lupold, S.E., Forrester, K., Xu, G., Elmore, L., Yeh, H., Hoeijmakers, J.H.J., and Harris, C. "The XPB and XPD helicases are components of the p53-mediated apoptosis pathway" . Genes Dev . 10: 1219-1232, 1996

Wang, X.W., and Harris, C.C. "p53 Tumor-suppressor gene: Clues to molecular carcinogenesis" . J. Cell. Physiol . 173: 247-255 , 1997

Wang-Gohrke, S., Hees, S., Pochon, A., Wen, W.H., Reles, A., Press, M.F., Kreienberg, R., and Runnebaum, I.B . "Genomic semi-automated cycle sequencing as a sensitive screening technique for p53 mutations in frozen tumor samples." Oncol. Rep . 5: 65-68, 1998

Wang-Gohrke, S., Weikel, W., Risch, H., Vesprini, D., Abrahamson, J., Lerman, C., Godwin, A., Moslehi, A., Olipade, O., Brunet, J.-S., Stickeler, E., Kieback, D.G., Kreienberg, R., Weber, B., Narod, S.A., and Runnebaum, I.B . "Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations." Br. J. Cancer 81 : 179-183, 1999


Weinstein, J.N., Myers, T.G., O‘Connor, P.M., Friend, S.H., Fornace, A.J.Jr., Kohn, K.W., Fojo, T., Bates, S.E., Rubinstein, L.V., Anderson, N.L., Buolamwini, J.K., van Osdol, W.W., Monks, A.P., Scudiero, D.A., Sausville, E.A., Zaharevitz, D.W., Bunow, B., Viswanadhan, V.N., Johnson, G.S., Wittes, R.E., and Paull, K.D . "An Information-Intensive Approach to the Molecular Pharmacology of Cancer." Science 275: 343-349, 1997

Wen, H.W., Reles, A., Runnebaum, I.B., Sullivan-Halley, J., Bernstein, L., Jones, L.A., Felix, J.C., Kreienberg, R., El-Naggar, A., and Press, M.F. "p53 mutations and expression in ovarian cancers: Correlation with overall survival." Int. J. Gyn. Pathol . 18: 29-41, 1999

Werness, B.A., Freedman, A.N., Piver, M.S., Romero-Guiterrez, M., and Petrow, E . "Prognostic significance of p53 and p21waf1/cip1 immunoreactivity in epithelial cancers of the ovary" . Gynecol. Oncol . 75: 413-418 , 1999

Wertheim, I., Muto, M., Welch, W., Bell, D., Berkowitz, R., and Mok, S . "p53 gene mutations in human borderline epithelial ovarian tumors." J. Natl. Cancer Inst . 86: 1549-51 , 1994

Weston, A., Perrin, L.S., Forrester, K., Hoover, R.N., Trump, B.F., Harris, C.L., and Caparaso, N.E . "Allelic frequency of a p53 polymorphism in human lung cancer." Cancer Epidemiol. Biomarkers Prev . 1 : 481-483 , 1992

Whittemore, A.S., Harris, R., and Itnyre, J. "Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women" . Am. J. Epidemiol. 136: 1184-1203 , 1992

Whittemore, A.S., Gong, G., and Itnyre, J . "Prevalance and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer." Am. J. Hum. Genet . 60: 496-504 , 1997

Wills, K.N., Maneval, D.C., Menzel, P., Harris, M.P., Sutjipto, S., Vaillancourt, M.-T., Huang, W.M., Johnson, D.E., Anderson, S.C., Wen, S.F . "et al. Development and characterization of recombinant adenoviruses encoding p53 for gene therapy of cancer." Human Gene Ther . 5 : 1079-1088 , 1994

Wong, Y.F., Chung, T.K., Cheung, T.H., Nobori, T., Yu, A.L., Yu, J., Batova, A., Lai, K.W., Chang, A.M. "Methylation of p16INK4A in primary gynecologic malignancy." Cancer Lett. 136: 231-235 , 1999

Woo, R.A., McLure, K.G., Lees-Miller, S.P., Rancourt, D.E., and Lee, P.W.K . "DNA-dependent protein kinase acts upstream of p53 in response to DNA damage." Nature 394 : 700-704, 1998

Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S., Gumbs, C., and Micklem, G . "Identification of the breast cancer susceptibility gene BRCA2. " Nature 378: 789-791 , 1995

Xiong, Y., Hannon, G.J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. "p21 is a universal inhibitor of cyclin kinases. " Nature 366: 701-704 , 1993


Yin, Y., Terauchi, Y., Solomon, G.G., Aizawa, S., Rangarajan, P.N., Yazaki, Y., Kadowaki, T., and Barrett, J.C ". Involvement of p85 in p53-dependent apoptotic response to oxidative stress" . Nature 391: 707-710 , 1998

Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A., and Oren, M. "Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6." Nature 352 : 345-347 , 1991

van der Zee, A.G., Hollema, H., Suurmeijer, A.J., Krans, M., Sluiter, W.J., Willemse, P.H., Aalders, J.G., and de Vries, E.G. "Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas." J. Clin. Oncol. 13: 70-78 , 1995

Zhan, Q., Antinore, M.J., Wang, X.W., Carrier, F., Smith, M.L., Harris, C.C., Fornace, A.J. "Association with Cdc2 and inhibition of Cdc2/Cyclin B1 kinase activity by the p53-regulated protein Gadd45" . Oncogene 18 : 2892-900 , 1999

Zhang, H., Hannon, G., and Beach, D. "p21-containing cyclin kinases exist in both active and inactive states" . Gene Dev . 8 : 1750-1758 , 1994

Zhang, Y., Xiong, Y., and Yarbrough, W.G . "ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways." Cell 92 : 725-734 , 1998

Zheng, J., Benedict, W., Xu, H., Hu, S., Kim, T., Velicescu, M., Wan, M., Cofer, K., and Dubeau, L ". Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadenomas" . J. Natl. Cancer Inst . 87 : 1146-1153, 1995

Zauberman, A., Barak, Y., Ragimov, N., Levy, N., and Oren, M. "Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53-MDM2 complexes." EMBO J . 12: 2799-2808 , 1993

Zehbe, I., Voglino, G., Wilander, E., Genta, F., and Tommasino, M . "Codon 72 polymorphism of p53 and its association with cervical cancer" . Lancet 354 : 218-219 , 1999

© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.

DiML DTD Version 2.0
Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML - Version erstellt am:
Thu Aug 15 15:17:40 2002